P.MizunoG
Retatrutide Side Effects Are Similar to Existing Diabetes and Obesity Injectables The most common side effects for retatrutide were: Nausea (16 to 27 percent of participants, depending on dosage, compared with 3.7 percent of those taking a placebo) Diarrhea (19 to 23 percent, compared with 5 percent taking a placebo) Vomiting (16 to 18 percent, compared with 2 percent taking a placebo) Nerve issues (2 to 4 percent, compared with none taking a placebo) Between 2 and 5 percent of participants on retatrutide stopped taking it before the trial ended, with a greater risk of stopping among those who took the highest dose
Guided by many promising preclinical studies that potentially link GSH and oxidative stress with the pathophysiology of SZ, multiple groups have also conducted clinical studies and measured GSH levels in peripheral blood of patients with SZ
The final database search was executed on January 10, 2025, without imposing restrictions on publication year or language to ensure maximum capture of relevant studies
Importantly, the narrative is balanced by acknowledging null findings, such as the study by Shirazi-Beechey et al
